Long-term follow-up of myelodysplastic syndrome patients with moderate/severe anaemia receiving human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3: independent positive impact of erythroid response on survival

British Journal of Haematology
Elena CrisàDario Ferrero

Abstract

We previously reported a 60% erythroid response rate with recombinant erythropoietin + 13-cis retinoic acid + dihydroxylated vitamin D3 in 63 elderly myelodysplastic patients (median age 75 years) with unfavourable features for response to erythropoietin alone [70% transfusion-dependent, 35% refractory anaemia with ring sideroblasts/refractory anaemia with excess of blasts type 1 (RAEB1), 70% with International Prognostic Scoring System (IPSS) Intermediate-1 or -2]. This report updates that case study at a 7-year follow-up, and compared the impact on overall survival of erythroid response to known prognostic factors. The erythroid response duration (median 17 months; 22 in non-RAEB patients, with 20% patients in response after 6 years of therapy) was longer than in most studies with erythropoietin alone. Overall survival (median 55 months in non-RAEB, 15 in RAEB1 patients) was negatively affected by RAEB1 diagnosis, IPSS and WPSS intermediate scores and transfusion-dependence. In the multivariate analysis, erythroid response maintained an independent positive impact on survival, particularly in non-RAEB patients in the first 3 years from diagnosis (90% survival compared to 50% of non-responders). In conclusion, the long-term fo...Continue Reading

References

Jan 11, 2005·British Journal of Haematology·Pellegrino MustoAngelo Michele Carella
Sep 17, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R StasiS Amadori
May 10, 2006·British Journal of Haematology·L MannoneUNKNOWN Groupe Francais des Myelodysplasies
Nov 23, 2006·Cancer·Pilar GiraldoUNKNOWN Aranesp in Myelodysplastic Syndromes (ARM) Study Group
Aug 10, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Luca MalcovatiMario Cazzola
Oct 18, 2007·Blood·Sophie ParkUNKNOWN GFM group (Groupe Francophone des Myélodysplasies)
Jun 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martin JäderstenEva Hellström-Lindberg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.